e-learning
resources
ERJ
2009
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy?
Hoeper M. M.
Source:
Eur Respir J 2009; 34: 529
Journal Issue:
September
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Hoeper M. M.. Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy?. Eur Respir J 2009; 34: 529
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
The Achilles heel of endothelin receptor therapy for pulmonary arterial hypertension
Source: Eur Respir J 2010; 35: 460-461
Year: 2010
Dual endothelin receptor antagonism: setting standards in PAH
Source: Eur Respir Rev 2008; 17: 13-18
Year: 2007
The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan
Source: Annual Congress 2010 - Airway smooth muscle cells
Year: 2010
Late Breaking Abstract: Anti-fibrogenic effects of the endothelin-A receptor antagonist ambrisentan in a mouse pulmonary fibrosis model
Source: Annual Congress 2010 - Animal models of asthma and lung inflammation
Year: 2010
Vasopressin is involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonists
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012
Confidence from experience: dual endothelin receptor antagonism in PAH
Source: Eur Respir Rev 2008; 17: 1-2
Year: 2007
Single centre experience with endothelin receptor blockade in pulmonary hypertension
Source: Annual Congress 2004 - Pulmonary hypertension
Year: 2004
Endothelin: setting the scene in PAH
Source: Eur Respir Rev 2008; 17: 3-7
Year: 2007
Dual endothelin receptor blockade: advances in pulmonary disease
Source: Annual Congress 2008 - Mastering pulmonary arterial hypertension: defined by evidence - enhanced by experience
Year: 2008
Monitoring of liver function in patients with pulmonary hypertension treated with endothelin receptor antagonists: The value of a novel monitoring system
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011
Superior in vivo efficacy of macitentan: Comparison to other endothelin receptor antagonists
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012
Late Breaking Abstract - The neurokinin-1 receptor antagonist orvepitant improves chronic cough symptoms: results from a Phase 2b trial
Source: International Congress 2019 – Highlights in lung function and chronic cough
Year: 2019
Selective
versus
non-selective endothelin receptor antagonists
Source: Annual Congress 2005 - New treatments in pulmonary hypertension
Year: 2005
Efficacy of sitaxsentan, an endothelin-A receptor antagonist in PAH in traditional vs. expanded study populations
Source: Eur Respir J 2004; 24: Suppl. 48, 109s
Year: 2004
Is there a link between long-term endothelial receptor antagonists therapy and carcinogenesis in PAH: A case series?
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011
Endothelin receptor antagonists in pulmonary arterial hypertension
Source: Eur Respir J 2008; 31: 407-415
Year: 2008
Novel approach to prevention of dust-induced acute lung injury with interleukin-1 receptor antagonist (IL-1ra)
Source: Eur Respir J 2003; 22: Suppl. 45, 459s
Year: 2003
Abrogation of bleomycin induced inflammation and lung fibrosis by angiotensin AT1 receptor antagonist. Relevance of PGE-2 modulation
Source: Eur Respir J 2005; 26: Suppl. 49, 82s
Year: 2005
An open-label pilot study of memantine, an N-methyl-D-aspartate receptor antagonist in chronic cough
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept